亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

医学 威罗菲尼 阿替唑单抗 中期分析 内科学 安慰剂 耐受性 肿瘤科 外科 不利影响 随机对照试验 彭布罗利珠单抗 转移性黑色素瘤 癌症 免疫疗法 病理 替代医学
作者
Paolo A. Ascierto,Daniil Stroyakovskiy,Helen Gogas,Caroline Robert,Karl D. Lewis,Светлана Проценко,Rodrigo Perez Pereira,Thomas Eigentler,Piotr Rutkowski,Lev Demidov,Natalia V. Zhukova,Jacob Schachter,Yibing Yan,Ivor Caro,Christian Hertig,Cloris Xue,Lieke Kusters,Grant A. McArthur,Ralf Gutzmer
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:24 (1): 33-44 被引量:95
标识
DOI:10.1016/s1470-2045(22)00687-8
摘要

Primary analysis of the phase 3 IMspire150 study showed improved investigator-assessed progression-free survival with first-line atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) versus placebo, vemurafenib, and cobimetinib (control group) in patients with BRAFV600 mutation-positive melanoma. With a median follow-up of 18·9 months (IQR 10·4-23·8) at the primary analysis, overall survival data were immature. Here, we report the results from the second, prespecified, interim overall survival analysis.The multicentre, double-blind, placebo-controlled, randomised, phase 3 IMspire150 study was done at 108 academic and community hospitals in 20 countries. Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion. Patients were randomly assigned (1:1) to receive either atezolizumab (840 mg intravenously on day 1 and 15) or placebo plus vemurafenib (960 mg or 720 mg twice daily orally) and cobimetinib (60 mg once daily orally; 21 days on and 7 days off) in 28-day cycles. Atezolizumab and placebo were added to treatment regimens from cycle two onwards. Randomisation was done centrally (Durham, NC, USA) based on a permuted block randomisation scheme (block size of 4) using an interactive web-based response system and was stratified by geographical region and baseline lactate dehydrogenase concentration. Overall survival was analysed in the intention-to-treat population and safety was analysed in all patients who received at least one dose of study drug according to actual treatment received. The primary endpoint was investigator-assessed progression-free survival, which was previously reported. Here, we report the second, prespecified, interim overall survival analysis, which was planned after about 270 overall survival events had occurred. The trial is ongoing, but is no longer enrolling patients, and it is registered with ClinicalTrials.gov, NCT02908672.Between Jan 13, 2017, and April 26, 2018, 514 patients (median age 54 years [IQR 43-63]; 299 [58%] men and 215 [42%] women) were enrolled in the trial and randomly assigned to the atezolizumab group (256 [50%] patients) or the control group (258 [50%] patients). At the data cutoff (Sept 8, 2021), 273 patients had died (126 in the atezolizumab group and 147 in the control group). Median follow-up was 29·1 months (IQR 10·1-45·4) for the atezolizumab group versus 22·8 months (10·6-44·1) for the control group. Median overall survival was 39·0 months (95% CI 29·9-not estimable) in the atezolizumab group versus 25·8 months (22·0-34·6) in the control group (HR 0·84 [95% CI 0·66-1·06]; p=0·14). The most common adverse events of any grade in the atezolizumab group were blood creatine phosphokinase increased (123 [53%] of 231 patients), diarrhoea (116 [50%]), and pyrexia (115 [50%]). The most common adverse events of any grade in the control group were diarrhoea (157 [56%] of 280 patients), blood creatine phosphokinase increased (135 [48%]), and rash (119 [43%]). The most common grade 3-4 adverse events were increased lipase (54 [23%] of 231 patients in the atezolizumab group vs 62 [22%] of 280 patients in the control group), increased blood creatine phosphokinase (51 [22%] vs 50 [18%]), and increased alanine aminotransferase (32 [14%] vs 26 [9%]). Serious adverse events were reported in 112 (48%) patients in the atezolizumab group and 117 (42%) patients in the control group. Grade 5 adverse events were reported in eight (3%) patients in the atezolizumab group versus six (2%) patients in the control group. Two grade 5 adverse events (hepatitis fulminant and hepatic failure) in the atezolizumab group were considered to be associated with the triplet combination, and one event in the control group (pulmonary haemorrhage) was considered to be associated with cobimetinib.Additional follow-up of the IMspire150 trial showed that overall survival was not significantly improved with atezolizumab, vemurafenib, and cobimetinib compared with placebo, vemurafenib, and cobimetinib in patients with BRAFV600 mutation-positive advanced melanoma. Results of the final analysis are awaited to establish whether a significant improvement in overall survival can be achieved with long-term treatment with this triplet combination versus vemurafenib plus cobimetinib.F Hoffmann-La Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
美丽代桃完成签到,获得积分10
1秒前
15秒前
科研通AI6.2的应助被zihao采纳,获得10
16秒前
16秒前
贪玩的梦容完成签到,获得积分10
19秒前
369ninja发布了新的文献求助10
21秒前
重要的代荷完成签到,获得积分10
32秒前
33秒前
null的应助被科研通管家采纳,获得10
39秒前
null的应助被科研通管家采纳,获得10
39秒前
zihao发布了新的文献求助10
39秒前
null的应助被科研通管家采纳,获得10
39秒前
48秒前
1分钟前
1分钟前
1分钟前
所所的应助被落润晓采纳,获得10
1分钟前
缓慢凛完成签到,获得积分10
1分钟前
1分钟前
1分钟前
Ccccn完成签到,获得积分10
1分钟前
落润晓发布了新的文献求助10
1分钟前
agathahqs的应助被初景采纳,获得10
1分钟前
1分钟前
超级的愫完成签到,获得积分10
1分钟前
1分钟前
1分钟前
2分钟前
不安雅霜完成签到,获得积分10
2分钟前
2分钟前
DR_MING完成签到,获得积分10
2分钟前
DR_MING发布了新的文献求助10
2分钟前
zsmj23完成签到 ,获得积分0
2分钟前
2分钟前
2分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
2分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
2分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
2分钟前
科研通AI6.2的应助被纯情的阁采纳,获得30
2分钟前
科研通AI6.4的应助被纯情的阁采纳,获得10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158792
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719316
捐赠科研通 7748395
什么是DOI,文献DOI怎么找? 3427099
关于科研通互助平台的介绍 2551987
邀请新用户注册赠送积分活动 2471354